logo
logo
Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc.

NASDAQ•CTNM
CEO: Mr. Carmine N. Stengone MBA, MS
セクター: Healthcare
業種: Biotechnology
上場日:
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
連絡先情報
10578 Science Center Drive, Suite 200, San Diego, CA, 92121, United States
858-333-5280
www.contineum-tx.com
時価総額
$543.56M
PER (TTM)
-7.0
33.3
配当利回り
--
52週高値
$16.01
52週安値
$3.35
52週レンジ
91%
順位59Top 87.6%
2.2
F-Score
改良版 Piotroski 分析
4年ファンダメンタル
弱い • 2.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2022-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$0.45+12.50%
直近4四半期の推移

フリーCF

-$12.30M+96.69%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Strong Liquidity Position Cash reserves total $182.4M; sufficient funding projected for operations spanning at least 12 months from issuance date.
R&D Investment Surge Nine months R&D expenses hit $38.8M, up $13.4M, driven by PIPE-791 clinical trial acceleration efforts.
Pipeline Advancement Milestones Advancing PIPE-307 RRMS Phase 2 trial enrollment completion; topline data anticipated in the fourth quarter of 2025.
ATM Program Proceeds Realized Raised $19.0M net proceeds during the quarter via Class A stock sales under the May 2025 ATM Sales Agreement.

リスク要因

Widening Quarterly Net Loss Quarterly net loss widened to $(12.8M) in Q3 2025 from $(10.3M) in Q3 2024, due to increased operating expenses.
Escalating R&D Cost Structure R&D costs increased $13.4M over nine months, reflecting high external costs for advancing PIPE-791 clinical programs.
Future Financing Dependency Continued net losses necessitate external financing; assurance is lacking for securing future capital on acceptable terms if needed.
Clinical Execution Uncertainty Successful clinical trial completion and regulatory approval for drug candidates remain highly uncertain factors impacting future value.

見通し

PIPE-791 IPF Trial Initiation Planning initiation of global Phase 2 clinical trial for wholly-owned asset PIPE-791 in IPF indication during Q4 2025.
G&A Expense Increase Expected Expect G&A expenses to increase supporting headcount growth and compliance costs associated with maintaining public company status.
Expanding Discovery Portfolio Actively pursuing preclinical and discovery-phase experiments to expand clinical portfolio targeting additional NI&I indications.
PIPE-791 Pain Trial Data Anticipate receiving topline data from the PIPE-791 chronic pain Phase 1b trial during the first half of 2026.

同業比較

売上高 (TTM)

Amarin Corporation plcAMRN
$225.62M
-6.7%
Vanda Pharmaceuticals Inc.VNDA
$216.11M
+8.7%
Editas Medicine, Inc.EDIT
$46.38M
-24.9%

粗利益率 (最新四半期)

Editas Medicine, Inc.EDIT
100.0%
+2621.3pp
AC Immune SAACIU
100.0%
+0.0pp
Silence Therapeutics plcSLN
59.7%
+202.7pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CAPR$1.08B-13.2-71.0%11.5%
ANNX$620.70M-3.7-92.3%11.8%
CTNM$543.56M-7.0-32.3%2.9%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月5日
|
EPS:-$0.50
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月30日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.45+12.5%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月5日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.62+77.1%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月14日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.62+87.9%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月6日|
    売上高: $0.00-100.0%
    |
    EPS: $-2.18-342.2%
    不明

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.40+60.0%
    不明

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月14日|
    売上高: $0.00-100.0%
    |
    EPS: $-0.35-121.6%
    不明

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月16日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.33+73.7%
    不明